Business Context and Reporting Period
Apogee Therapeutics, Inc. (APGE) filed a Form 8-K on October 8, 2025, reporting the entry into a material definitive agreement for a public equity offering and providing updates on clinical trial milestones. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Offering Structure: Issuance of 6,951,221 shares of common stock at $41.00 per share and 365,853 pre-funded warrants at $40.99999 per share.
- Over-Allotment Option: Underwriters exercised their option in full on October 9, 2025, to purchase an additional 1,097,561 shares of common stock.
- Net Proceeds: Approximately $323.3 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Closing Date: Expected on October 10, 2025.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, or debt metrics; it is a current report focused on the capital raise and operational updates.
Material Changes and Operational Updates
The filing details significant updates to the company's clinical development timeline for its lead asset, APG777:
- APEX Phase 2 Trial (Atopic Dermatitis): The expected patient population has increased to 320 patients. Enrollment for Part B is expected to be completed by the end of 2025.
- Data Readouts: Topline maintenance data from Part A is now expected in Q1 2026. Topline 16-week induction data from Part B is expected in Q2 2026.
- Phase 1b Trial (Asthma): Topline data is now expected in Q1 2026.
Guidance, Risks, and Contingencies
Management has provided updated guidance regarding clinical trial enrollment and data readout dates, indicating a shift in the timeline for key milestones. The filing notes standard indemnification obligations to underwriters regarding liabilities under the Securities Act of 1933. No specific financial risks or contingencies beyond the standard terms of the underwriting agreement are detailed in this text.
Key Facts for Investor Verification
- Verify the final closing of the offering and the actual net proceeds received on or after October 10, 2025.
- Confirm the dilution impact of the 8,048,782 total shares issued (including the over-allotment) and the pre-funded warrants.
- Monitor the Q1 and Q2 2026 data readouts for APG777 in atopic dermatitis and asthma as the primary catalysts for future valuation.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and registration rights.